GSK’s two-speed strategy reflects a calculated attempt to balance innovation with risk mitigation. The strongest version of this narrative is that GSK is leveraging external partnerships to cast a wide net for early-stage science while reserving significant investments for assets with proven biology. This approach aligns with industry trends where large pharma companies increasingly rely on external innovation to replenish pipelines. However, the strategy’s coherence depends on whether these dis...